Tag
Regeneron Pharmaceuticals, Inc.
- Genmab A/S reports 51% lower progression or death risk in Phase 3 lymphoma trial
- Nektar Therapeutics wins US$90M jury award in Lilly licence case
- REGENXBIO reports three-year retinopathy improvement in 6 of 10
- Merck says remigromig met BRUNELLO vision endpoint, flags eye risks
- Regeneron Pharmaceuticals gets access to biometric data for 15 million people